Clinical Trial Update: A Study to Learn About the Investigational Medicine Called PF-06821497 (Mevrometostat) in Men With mCRPC Who Were Previously Treated With Abiraterone Acetate for Prostate Cancer (MEVPRO-1). [Phase 3]

View source ↗

Summary

A Phase 3 clinical trial update for PF-06821497 (Mevrometostat) in men with metastatic castration-resistant prostate cancer who previously received abiraterone;…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Castration-resistant Prostate Cancer

Drugs mentioned

• PF-06821497 (Mevrometostat) (Mevrometostat)

Snippet

Sponsor: Pfizer | Conditions: Metastatic Castrate Resistant Prostate Cancer (mCRPC) | Phase 3 | Status: RECRUITING